Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Tolerability of Letetresgene Autoleucel (Lete-cel; GSK3377794): Pilot Studies in Patients With Advanced Non-Small Cell Lung Cancer.
Altan M, Lopes G, Hiltermann TJN, Govindan R, Villaruz LC, Calvo E, Edelman MJ, Furqan M, Neal J, Felip E, Carlisle JW, Heymach JV, O'Cearbhaill RE, Zauderer M, Chisamore M, Corigliano E, Eleftheriadou I, Zajic S, Jenkins B, Goodison S, Suchindran S, Ramos-Hernandez N, Tarek N, Schoenfeld AJ. Altan M, et al. Among authors: zajic s. Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-1591. Online ahead of print. Clin Cancer Res. 2024. PMID: 39576208
Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.
Kuchimanchi M, Jørgensen TL, Hanze E, André T, Jain A, Berton D, Alskär O, Zub O, Oaknin A, Shahin MS, Koliadi A, Pothuri B, Krivak T, Pishchyk M, Segev Y, Backes FJ, Gennigens C, Bouberhan S, Zajic S, Melhem M, Buscema J. Kuchimanchi M, et al. Among authors: zajic s. Br J Clin Pharmacol. 2024 Nov 8. doi: 10.1111/bcp.16325. Online ahead of print. Br J Clin Pharmacol. 2024. PMID: 39520048
Niraparib Population Pharmacokinetics and Exposure-Response Relationships in Patients With Newly Diagnosed Advanced Ovarian Cancer.
Monk BJ, Romero I, Graybill W, Churruca C, O'Malley DM, Knudsen AØ, Yap OWS, Baurain JF, Rose PG, Denys H, Ghamande S, Pisano C, Fabbro M, Braicu EI, Calvert PM, Amit A, Prendergast E, Taylor A, Kheibarshekan L, Zhang ZY, Zajic S, Jewell RC, Gupta D, González-Martín A. Monk BJ, et al. Among authors: zajic s. Clin Ther. 2024 Aug;46(8):612-621. doi: 10.1016/j.clinthera.2024.06.001. Epub 2024 Jul 16. Clin Ther. 2024. PMID: 39019698 Free article.
Postmortem toxicology findings from the Camden Opioid Research Initiative.
Kusic DM, Heil J, Zajic S, Brangan A, Dairo O, Heil S, Feigin G, Kacinko S, Buono RJ, Ferraro TN, Rafeq R, Haroz R, Baston K, Bodofsky E, Sabia M, Salzman M, Resch A, Madzo J, Scheinfeldt LB, Issa JJ, Jelinek J. Kusic DM, et al. Among authors: zajic s. PLoS One. 2023 Nov 1;18(11):e0292674. doi: 10.1371/journal.pone.0292674. eCollection 2023. PLoS One. 2023. PMID: 37910493 Free PMC article.
Patient Perceptions and Potential Utility of Pharmacogenetic Testing in Chronic Pain Management and Opioid Use Disorder in the Camden Opioid Research Initiative.
Kusic D, Heil J, Zajic S, Brangan A, Dairo O, Smith G, Morales-Scheihing D, Buono RJ, Ferraro TN, Haroz R, Salzman M, Baston K, Bodofsky E, Sabia M, Resch A, Scheinfeldt LB. Kusic D, et al. Among authors: zajic s. Pharmaceutics. 2022 Sep 3;14(9):1863. doi: 10.3390/pharmaceutics14091863. Pharmaceutics. 2022. PMID: 36145611 Free PMC article.
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.
Gyurdieva A, Zajic S, Chang YF, Houseman EA, Zhong S, Kim J, Nathenson M, Faitg T, Woessner M, Turner DC, Hasan AN, Glod J, Kaplan RN, D'Angelo SP, Araujo DM, Chow WA, Druta M, Demetri GD, Van Tine BA, Grupp SA, Fine GD, Eleftheriadou I. Gyurdieva A, et al. Among authors: zajic s. Nat Commun. 2022 Sep 8;13(1):5296. doi: 10.1038/s41467-022-32491-x. Nat Commun. 2022. PMID: 36075914 Free PMC article.
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.
Akce M, El-Khoueiry A, Piha-Paul SA, Bacque E, Pan P, Zhang ZY, Ewesuedo R, Gupta D, Tang Y, Milton A, Zajic S, Judson PL, O'Bryant CL. Akce M, et al. Among authors: zajic s. Cancer Chemother Pharmacol. 2021 Nov;88(5):825-836. doi: 10.1007/s00280-021-04329-8. Epub 2021 Jul 29. Cancer Chemother Pharmacol. 2021. PMID: 34324028 Free PMC article. Clinical Trial.
The Genomics of Opioid Addiction Longitudinal Study (GOALS): study design for a prospective evaluation of genetic and non-genetic factors for development of and recovery from opioid use disorder.
Heil J, Zajic S, Albertson E, Brangan A, Jones I, Roberts W, Sabia M, Bodofsky E, Resch A, Rafeq R, Haroz R, Buono R, Ferraro TN, Scheinfeldt L, Salzman M, Baston K. Heil J, et al. Among authors: zajic s. BMC Med Genomics. 2021 Jan 7;14(1):16. doi: 10.1186/s12920-020-00837-3. BMC Med Genomics. 2021. PMID: 33413350 Free PMC article.
31 results